Screening of Biomarkers and Related Mechanisms for RIX
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Radiation Therapy.
- Who it may be relevant to
- Registry conditions: Xerostomia Due to Radiotherapy (Disorder). Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Screening of Diagnostic Biomarkers and Related Mechanisms for Radiation-induced Xerostomia
Overview
A large number of patients undergoing radiotherapy and chemotherapy are suffering from dry mouth. Due to reduced saliva secretion, patients may experience symptoms such as difficulty chewing and swallowing. In severe cases, they may also experience pain and burning sensation in the oral mucosa, decreased taste, ulcers, which seriously affect the quality of life of patients. However, radiation-induced dry mouth lacks early objective predictive indicators (molecular biomarkers) and the mechanism is unclear. Only when patients experience clinical symptoms will symptomatic treatment be taken to alleviate them. Therefore, elucidating the mechanism of radiation-induced dry mouth syndrome (RIX) and achieving early prediction, detection, and intervention of RIX are crucial in improving the prognosis and quality of life of radiotherapy patients. It is urgent to seek early and precise detection targets in clinical practice to predict dry mouth caused by irreversible damage to salivary gland tissue. This study aims to collect blood samples from patients with severe dry mouth before and after radiotherapy and chemotherapy in clinical practice. Multiple omics techniques will be used to search for predictive molecular biomarkers for RIX, construct a predictive model, and verify the sensitivity and specificity of the biomarkers. The goal is to predict the occurrence of RIX early in clinical practice, intervene in advance, greatly improve the prognosis of radiotherapy and chemotherapy patients, and enhance their quality of life.
Interventions
- Radiation Radiation Therapy
Radiotherapy for Head and Neck Cancer Patients
Primary outcome measures
- Resting saliva flow measurement [Time frame: From the start of radiotherapy to 3 months after completion]
Secondary outcome measures (2)
- Changes in Quality of Life and xerostomia Questionnaire Scores [Time frame: From the start of radiotherapy to 3 months after completion]
- Comparison of Body Mass Index [Time frame: From the start of radiotherapy to 3 months after completion]
Eligibility criteria
Inclusion criteria
- Histological diagnosis of head and neck cancer;
- Plan to undergo curative treatment with radiotherapy alone or in combination with synchronous chemotherapy, immunotherapy, or targeted therapy;
- Age greater than or equal to 18 years old, Fully understand the purpose and significance of this study, voluntarily participate and sign an informed consent form.
Exclusion criteria
- Metastatic diseases;
- History of head and neck radiotherapy;
- Severe dry mouth before radiotherapy;
- Suffering from advanced chronic diseases: heart failure - New York Heart Association functional classification III/IV, renal failure - estimated glomerular filtration rate under 30mL/min/1.73m2, liver failure - Child Pugh score C or D.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 4 centers
- The First Affiliated Hospital of Nanjing Medical University — Nanjing
- Affiliated Jinling Hospital, Medical School of Nanjing University — Nanjing
- Jiangsu Cancer Hospital — Nanjing
- The Second Affiliated Hospital of Zhejiang University School of Medicine — Hangzhou
Identifiers
NCT: NCT07170358 · 2025-0461